Interestingly, upregulation of the EGFR pathway (including several of its ligands, as TGFA, HBEGF, and CTGF) has been described in human and experimental chronic renal pathologies, including glomerulonephritis, diabetic nephropathy, transplant rejection, and polycystic kidney disease [63–65], as well as in experimental models of acute kidney injury (AKI), such as ischemia/reperfusion or folic acid administration [66–68]. The gene discussed is TGFA; the disease is acute kidney injury.